Denmark ditches J&J COVID-19 shots from vaccination programme


Johnson & Johnson’s coronavirus illness (COVID-19) vaccines are saved refrigerated on the Forem vaccination centre in Pamplona, Spain, April 22, 2021. REUTERS/Vincent West

Denmark on Monday turned the primary nation to exclude Johnson & Johnson’s (JNJ.N) COVID-19 photographs from its vaccination programme over a possible hyperlink to a uncommon however severe type of blood clot.

The transfer comes after the Nordic nation final month stopped utilizing AstraZeneca’s (AZN.L) vaccine altogether citing comparable issues. learn extra

The nation’s well being authority mentioned in an announcement it had discovered that “the advantages of utilizing the COVID-19 vaccine from Johnson & Johnson don’t outweigh the chance of inflicting the attainable antagonistic impact in those that obtain the vaccine”.

Excluding the J&J vaccine, which accounts for round a 3rd of Denmark’s whole contracted provides of COVID-19 photographs, would delay the nation’s vaccination calendar by as much as 4 weeks, it mentioned.

Denmark, which has to date totally vaccinated 11.5% of its inhabitants, has progressively been reopening society since early March as an infection charges has slowed, together with indoor service at eating places and cafes and permitting soccer followers into stadiums.

“Taking the current state of affairs in Denmark into consideration, what we’re presently dropping in our effort to stop extreme sickness from COVID-19 can not outweigh the chance of inflicting attainable unwanted effects within the type of extreme blood clots in these we vaccinate,” the well being authority mentioned.

It added that the vaccination rollout is progressing satisfactorily with different out there vaccines.

Lawmakers at a gathering on Monday agreed to permit voluntary use of the photographs from each Johnson & Johnson and AstraZeneca, lawmaker Liselott Blixt of the Danish Folks’s Celebration advised Reuters.

The rollout of J&J’s vaccine has additionally been delayed elsewhere in Europe over comparable clotting issues.

Europe’s drug regulator, the European Medicines Company, mentioned on April 20 it had discovered a attainable hyperlink between J&J’s vaccine and uncommon blood clotting points in adults who acquired doses in the US. learn extra

But it surely backed the vaccine’s total advantages in opposition to any dangers. Since then, a number of European international locations have resumed administering the vaccine.

EMA mentioned its security committee had concluded {that a} warning about uncommon blood clots with low platelets should be added to the vaccine’s labels, simply as was required of AstraZeneca. J&J mentioned in a information launch that it will adjust to that measure.

Our Requirements: The Thomson Reuters Belief Ideas.


Please enter your comment!
Please enter your name here